Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin
Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of VB6-845 and to
evaluate the safety and tolerability of VB6-845 when administered as a monotherapy IV
infusion to patients with advanced solid tumour of epithelial origin.